168 related articles for article (PubMed ID: 29731877)
1. Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.
Liu H; Cheng J; Zhao L; Xu Q; Xue M; Zhang S; Liu B
Oncol Lett; 2018 May; 15(5):7132-7138. PubMed ID: 29731877
[TBL] [Abstract][Full Text] [Related]
2. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.
Deng Q; Li JY; Liu PJ; Zhao MF
Oncol Lett; 2015 Mar; 9(3):1217-1220. PubMed ID: 25663885
[TBL] [Abstract][Full Text] [Related]
3. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
4. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
Itzykson R; Santini V; Thepot S; Ades L; Chaffaut C; Giagounidis A; Morabito M; Droin N; Lübbert M; Sapena R; Nimubona S; Goasguen J; Wattel E; Zini G; Torregrosa Diaz JM; Germing U; Pelizzari AM; Park S; Jaekel N; Metzgeroth G; Onida F; Navarro R; Patriarca A; Stamatoullas A; Götze K; Puttrich M; Mossuto S; Solary E; Gloaguen S; Chevret S; Chermat F; Platzbecker U; Fenaux P
J Clin Oncol; 2023 Apr; 41(10):1888-1897. PubMed ID: 36455187
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].
Li X; Wang Y; Guo YJ; Niu ZY; Ma L; Zhou XQ; Zhang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):257-261. PubMed ID: 38387931
[TBL] [Abstract][Full Text] [Related]
6. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Santini V; Allione B; Zini G; Gioia D; Lunghi M; Poloni A; Cilloni D; Sanna A; Masiera E; Ceccarelli M; Abdel-Wahab O; Terenzi A; Angelucci E; Finelli C; Onida F; Pelizzari A; Ferrero D; Saglio G; Figueroa M; Levis A
Leukemia; 2018 Feb; 32(2):413-418. PubMed ID: 28607470
[TBL] [Abstract][Full Text] [Related]
7. A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.
Kim HJ; Park EK; Moon IS
Chin J Cancer Res; 2014 Feb; 26(1):E1-4. PubMed ID: 24653636
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
9. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
10. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Kidney Injury Associated with Transformation of Chronic Myelomonocytic Leukemia into Acute Myeloid Leukemia: A Case Report.
Lee SW; Kim MS; Kim YJ; Jung HY; Choi JY; Cho JH; Park SH; Kim CD; Kim YL; Lim JH
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256628
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
13. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
14. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
Castaño-Díez S; López-Guerra M; Bosch-Castañeda C; Bataller A; Charry P; Esteban D; Guijarro F; Jiménez-Vicente C; Castillo-Girón C; Cortes A; Martínez-Roca A; Triguero A; Álamo JR; Beà S; Costa D; Colomer D; Rozman M; Esteve J; Díaz-Beyá M
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077644
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
17. [High Risk Factors for Transformation into Acute myeloid Leukemia in Patients with Intermediate and High Risk Myelodysplastic syndrome].
Yang Q; Nie SM; Li TL; Huang JX; Liu SS; Gao Y; Yan XS; Mao CX; Meng FJ; Feng XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):558-566. PubMed ID: 32319396
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
de Lima M; Ravandi F; Shahjahan M; Andersson B; Couriel D; Donato M; Khouri I; Gajewski J; van Besien K; Champlin R; Giralt S; Kantarjian H
Cancer; 2003 Mar; 97(5):1242-7. PubMed ID: 12599231
[TBL] [Abstract][Full Text] [Related]
20. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Jin M; Hu Y; Wu W; Luo Y; Tan Y; Yu J; Jin A; Yang L; Huang H; Wei G
BMC Cancer; 2019 Mar; 19(1):242. PubMed ID: 30885156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
